Novavax (NVAX) Operating Leases (2020 - 2025)

Novavax's Operating Leases history runs 6 years deep, the most recent figure standing at $21.4 million for Q4 2025.

• On a quarterly basis, Operating Leases fell 72.03% year-over-year to $21.4 million in Q4 2025; TTM through Dec 2025 was $21.4 million, a 72.03% decrease from a year earlier, with the FY2025 full-year figure at $21.4 million, down 72.03% from the prior year.
• Operating Leases declined to $21.4 million in Q4 2025 per NVAX's latest filing, from $76.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $84.5 million in Q4 2023 and bottomed at $21.4 million in Q4 2025.
• The 5-year median for Operating Leases is $76.7 million (2024), against an average of $60.6 million.
• Across the five-year window, Operating Leases surged 107.9% in 2022 and sank 72.03% in 2025, its largest moves.
• Year by year, Operating Leases stood at $39.1 million in 2021, then jumped by 107.9% to $81.3 million in 2022, then climbed by 3.91% to $84.5 million in 2023, then fell by 9.25% to $76.7 million in 2024, then sank by 72.03% to $21.4 million in 2025.
• Per Business Quant, the three latest NVAX Operating Leases figures stand at $21.4 million (Q4 2025), $76.7 million (Q4 2024), and $84.5 million (Q4 2023).